We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ilika Plc | LSE:IKA | London | Ordinary Share | GB00B608Z994 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 27.00 | 26.00 | 28.00 | 27.00 | 27.00 | 27.00 | 27,251 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 702k | -7.3M | -0.0459 | -5.88 | 42.92M |
Date | Subject | Author | Discuss |
---|---|---|---|
16/7/2024 08:10 | Gravy train, much? “Ilikia is 100% grant funded with 2024 results confirming the largest operating expense was General & Administrative costs, amounting to UK£7.78m / 107% of total expenses” Nearly £8M p:ssed up the wall on hot air & Jam tomorrow waffle this year..according to ilika.. only another 6 years cash burn to go to (hopefully) reach Goliath commerciality hey kids, guess what else happens in exactly 6 years time? Graham Purdey turns 65 years old.. retirement time, LOL | phil2003 | |
12/7/2024 10:01 | https://www.director | kooba | |
11/7/2024 18:04 | Oh kenjen.. the perpetual glass half full average-downer I made a profit here, small, but a profit nevertheless I hope it works out for you | phil2003 | |
11/7/2024 15:37 | kenjen buy so more fella if your so confident. :) | rogk | |
11/7/2024 14:55 | So you are out today on no News even though the market has ilika up around 8%z. So we will be generous and say you sold today at 28p, probably nearer 27 in all honesty. Let’s see where this goes in the next 2 weeks and what your 28p sell looks like then. That’s seems fair as you seem like an individual of strong convictions. So your conviction is you got a good deal today. Let’s all see how that works out. Good luck 👍 | kenjen1 | |
11/7/2024 14:50 | There he is! The circus has arrived | kenjen1 | |
11/7/2024 14:28 | OK… So when will Ilkia’s EV battery (Goliath) be fully tested, commercially proven and viable (we hope) and available to buy I hear you say? 6 years time From RNS today.. “Current estimates are that the UK EV battery market will be worth ca. £9bn by 2030 and Ilika is positioning its technology to be ready for that opportunity." That’s alot of fund raises and alot more jam tomorrow & hot air, yawn.. just a bunch of grant funded academics gently drifting towards retirement. I’m OUT today on this no news, news.. my sell will be reported after hours. I can put my money to better use elsewhere. Good luck Kenjen and all you ilika faithfuls | phil2003 | |
11/7/2024 13:59 | Market likes the update and a few big buys going through. Are we finally at a turning point with both stereax and p1 Goliath samples being shipped this half of the year to a growing customer base? Fingers crossed | kenjen1 | |
11/7/2024 07:55 | That was meant to be in H2 25. Them deserve lots of credit on this one. | kenjen1 | |
11/7/2024 07:54 | Brilliant update from GP at the end of the RNS. Following the team's achievements we expect to be in the position to manufacture and deliver fully characterised P1 test pouch cells to customers in H2 2024 | kenjen1 | |
11/7/2024 07:37 | Read the RNS !!! Pre-pilot production facility targets capacity increase to 1.5 MWh/a Revenue mostly grant funded !!! Goliath pouch cells only P1 !!! Yawn | rogk | |
11/7/2024 07:34 | I had no idea that the Goliath 1.5mw pilot line had been installed already. Nice surprise but these sort of achievements seems to under the radar. Well not anymore. | kenjen1 | |
11/7/2024 07:17 | Revenue up Losses down Stereax manufacturing brought forward to H2 24 21 customers lined up for Stereax so far. Goliath pouch cells being produced earlier than expected in H2 24 17 commercial agreements in the pipeline That’s how to do an RNS. Well done all at Ilika, great progress. | kenjen1 | |
11/7/2024 07:12 | "Commercial interest and government grant support expected to intensify as the Goliath product continues to mature." | thiopia | |
10/7/2024 08:40 | Annual results tomorrow. Looking for an update on Stereax manufacturing and FDA. Goliath initial (non confidential) results from customer in house testing programme. There is no point running these if results can’t be shared with investors and other . potential customers. Think we should get some meaningful updates tomorrow :) | kenjen1 | |
10/7/2024 08:25 | I was the one who raised the FDA issue which GP answered in recent meetings. FDA is going to take a long long time. If you valued my opinion I could have saved you buying at higher prices. ;) | rogk | |
09/7/2024 17:00 | Just as well I don’t value your opinion then :) | kenjen1 | |
09/7/2024 08:08 | Your FDA expectations are wrong. IMO | rogk | |
06/7/2024 13:43 | FDA will be done this year or early 2025 for production ramp up as per published timelines. For every buy there is a sell. That is correct 👍 | kenjen1 | |
06/7/2024 12:24 | For every buy there is a sell. I think FDA will take years buddy. No real news for long long time me thinks. | rogk | |
06/7/2024 07:41 | Bought back in. There are some chunky buys being reported as late each day. Goliath have 2 current tests underway, one with customer onsite. One with customer offsite. Add to that the need to get Stereax FDA approved over the next few months then worth investing and holding now. Target 60p | kenjen1 | |
02/7/2024 19:08 | Is this fake or just wrong? hxxps://shorturl.at/ | tp5588 | |
02/7/2024 08:22 | I agree that lots of investors have lost interest in the battery sector after several bankruptcies. For Ilika however this is actually a big moment. After years of in-house development their Goliath product is now being evaluated by external parties. That could just start a scramble of strategic investment or obviously the reverse | robertspc1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions